Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection

Graham R Foster; Stephen Pianko; Ashley Brown; Daniel M Forton; Ronald G Nahass; Jacob George; Eleanor Barnes; Diana Brainard; Benedetta Massetto; Ming Lin; Bin Han; John G McHutchison; G Mani Subramanian; Curtis Cooper; Kosh Agarwal

doi:10.1053/j.gastro.2015.07.043

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection

Graham R Foster, Stephen Pianko, Ashley Brown, Daniel M Forton, Ronald G Nahass, Jacob George, Eleanor Barnes, Diana Brainard, Benedetta Massetto, Ming Lin, Bin Han, John G McHutchison, G Mani Subramanian, Curtis Cooper, Kosh Agarwal

Medicine Monash Health

Research output: Contribution to journal › Article › Research › peer-review

211 Citations (Scopus)

Abstract

Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA

Original language	English
Pages (from-to)	1462 - 1470
Number of pages	9
Journal	Gastroenterology
Volume	149
Issue number	6
DOIs	https://doi.org/10.1053/j.gastro.2015.07.043
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1053/j.gastro.2015.07.043

Cite this

Foster, G. R., Pianko, S., Brown, A., Forton, D. M., Nahass, R. G., George, J., Barnes, E., Brainard, D., Massetto, B., Lin, M., Han, B., McHutchison, J. G., Subramanian, G. M., Cooper, C., & Agarwal, K. (2015). Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology, 149(6), 1462 - 1470. https://doi.org/10.1053/j.gastro.2015.07.043

@article{85644ed9de57466fb15c64e85f65af23,

title = "Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection",

abstract = "Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA",

author = "Foster, {Graham R} and Stephen Pianko and Ashley Brown and Forton, {Daniel M} and Nahass, {Ronald G} and Jacob George and Eleanor Barnes and Diana Brainard and Benedetta Massetto and Ming Lin and Bin Han and McHutchison, {John G} and Subramanian, {G Mani} and Curtis Cooper and Kosh Agarwal",

year = "2015",

doi = "10.1053/j.gastro.2015.07.043",

language = "English",

volume = "149",

pages = "1462 -- 1470",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "Elsevier",

number = "6",

}

Foster, GR, Pianko, S, Brown, A, Forton, DM, Nahass, RG, George, J, Barnes, E, Brainard, D, Massetto, B, Lin, M, Han, B, McHutchison, JG, Subramanian, GM, Cooper, C & Agarwal, K 2015, 'Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection', Gastroenterology, vol. 149, no. 6, pp. 1462 - 1470. https://doi.org/10.1053/j.gastro.2015.07.043

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. / Foster, Graham R; Pianko, Stephen; Brown, Ashley et al.
In: Gastroenterology, Vol. 149, No. 6, 2015, p. 1462 - 1470.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection

AU - Foster, Graham R

AU - Pianko, Stephen

AU - Brown, Ashley

AU - Forton, Daniel M

AU - Nahass, Ronald G

AU - George, Jacob

AU - Barnes, Eleanor

AU - Brainard, Diana

AU - Massetto, Benedetta

AU - Lin, Ming

AU - Han, Bin

AU - McHutchison, John G

AU - Subramanian, G Mani

AU - Cooper, Curtis

AU - Agarwal, Kosh

PY - 2015

Y1 - 2015

N2 - Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA

AB - Background and Aims We conducted an open-label, randomized, phase 3 trial to determine the efficacy and safety of sofosbuvir and ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and hepatitis C virus (HCV) genotype 2 infection and treatment-naive or treatment-experienced patients with HCV genotype 3 infection. Methods The study was conducted at 80 sites in Europe, North America, Australia, and New Zealand Patients were randomly assigned (1:1:1) to groups given sofosbuvir and ribavirin for 16 weeks (n = 196); sofosbuvir and ribavirin for 24 weeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197). The primary end point was the percentage of patients with HCV RNA

UR - http://www.gastrojournal.org/article/S0016-5085(15)01069-0/pdf

U2 - 10.1053/j.gastro.2015.07.043

DO - 10.1053/j.gastro.2015.07.043

M3 - Article

SN - 0016-5085

VL - 149

SP - 1462

EP - 1470

JO - Gastroenterology

JF - Gastroenterology

IS - 6

ER -

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection

Abstract

UN SDGs

Access to Document

Other files and links

Cite this